An expert discusses how rilzabrutinib, a recently FDA-approved Bruton tyrosine kinase (BTK) inhibitor, targets the autoimmune pathophysiology of immune thrombocytopenia (ITP) by modulating B cells, ...
An expert discusses the rapidly evolving landscape of ITP treatments, highlighting emerging therapies such as Bruton’s tyrosine kinase inhibitors, neonatal Fc receptor antagonists, anti-CD38 ...
ITP can be chronic, but it may also go away on its own if it’s acute. Treatments may vary, depending on the type you have. Examples include splenectomy, corticosteroids, and platelet growth factors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results